Compare BENF & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BENF | TELA |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 31.4M |
| IPO Year | 2023 | 2019 |
| Metric | BENF | TELA |
|---|---|---|
| Price | $2.33 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 11.8K | ★ 287.4K |
| Earning Date | 02-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | $30.01 | $14.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.33 | $0.50 |
| 52 Week High | $9.96 | $1.73 |
| Indicator | BENF | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 34.17 | 57.43 |
| Support Level | $0.60 | $0.78 |
| Resistance Level | $3.84 | $0.96 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 21.88 | 62.15 |
Beneficient is a technology-enabled financial services holding company providing liquidity solutions and trust products and services to participants in the alternative assets industry through an online platform, AltAccess. Its services are focused on alternative asset investors, institutional investors, family offices, and fund managers. The company provides liquidity solutions for alternative asset investments through financing and trust structures. The company has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts. The majority of revenue is derived from the Ben Liquidity segment in the form of interest income.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.